INTS
NASDAQ · Biotechnology
Intensity Therapeutics Inc
$3.10
-0.18 (-5.49%)
Open$3.25
Previous Close$3.28
Day High$3.34
Day Low$3.10
52W High$15.75
52W Low$2.80
Volume—
Avg Volume12.6K
Market Cap9.79M
P/E Ratio—
EPS$-4.93
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,093.5% upside
Current
$3.10
$3.10
Target
$37.00
$37.00
$31.85
$37.00 avg
$43.82
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.04M | 2.78M | 2.85M |
| Net Income | -338,512 | -296,423 | -392,127 |
| Profit Margin | -11.1% | -10.7% | -13.8% |
| EBITDA | -526,054 | -452,617 | -411,641 |
| Free Cash Flow | -211,518 | -295,521 | -239,156 |
| Rev Growth | +8.4% | -9.6% | +19.4% |
| Debt/Equity | 0.32 | 0.33 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |